Neutralizing Aptamers Block S/RBD‐ACE2 Interactions and Prevent Host Cell Infection. Issue 18 (22nd March 2021)

• Record Type: Journal Article
• Authors: Liu, Xiaohui; Wang, Yi‐ling; Wu, Jacky; Qi, Jianjun; Zeng, Zihua; Wan, Quanyuan; Chen, Zhenghu; Manandhar, Pragya; Cavener, Victoria S.; Boyle, Nina R.; Fu, Xinping; Salazar, Eric; Kuchipudi, Suresh V.; Kapur, Vivek; Zhang, Xiaoliu; Umetani, Michihisa; Sen, Mehmet; Willson, Richard C.; Chen, Shu‐hsia; Zu, Youli
• Is Part Of: Angewandte Chemie international edition. Volume 60:Issue 18(2021)
• Page Start: 10273
• Page End: 10278
• Publication Date: 2021-03-22
• Subjects: aptamers -- COVID-19 -- receptor-binding domain (RBD) -- SARS-CoV-2 -- virus neutralization; Chemistry -- Periodicals; 540
• DOI: 10.1002/anie.202100345
• Languages: English
• ISSNs: 1433-7851

Abstract

Abstract: The receptor‐binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 spike (S) protein plays a central role in mediating the first step of virus infection to cause disease: virus binding to angiotensin‐converting enzyme 2 (ACE2) receptors on human host cells. Therefore, S/RBD is an ideal target for blocking and neutralization therapies to prevent and treat coronavirus disease 2019 (COVID‐19). Using a target‐based selection approach, we developed oligonucleotide aptamers containing a conserved sequence motif that specifically targets S/RBD. Synthetic aptamers had high binding affinity for S/RBD‐coated virus mimics ( K D ≈7 nM) and also blocked interaction of S/RBD with ACE2 receptors (IC50 ≈5 nM). Importantly, aptamers were able to neutralize S protein‐expressing viral particles and prevent host cell infection, suggesting a promising COVID‐19 therapy strategy. Abstract : Synthetic ssDNA aptamers containing a conserved sequence motif that specifically targets the receptor‐binding domain (RBD) of the SARS‐CoV‐2 spike have the capacity to neutralize the virus and prevent host cell infection in vitro, suggesting a new therapeutic approach to treat COVID‐19.